Identifying nasopharyngeal carcinoma patients with metachronous metastasis sensitive to local treatment: a real-world study

Fanyu Peng\textsuperscript{1,\Letter}, Yizhi Ge\textsuperscript{1,\Letter}, Rongrong Wang\textsuperscript{1,2}, Dingdong Hu\textsuperscript{1}, Xiang Cao\textsuperscript{1}, Yujie Zhang\textsuperscript{1}, Dan Zong\textsuperscript{1}, Xia He\textsuperscript{1,2,\Letter\Letter}

\textsuperscript{1}Department of Radiation Oncology, the Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu 210009, China; \textsuperscript{2}Xuzhou Medical University, Xuzhou, Jiangsu 221004, China.

Abstract

It is difficult for physicians to identify patients with metastatic nasopharyngeal carcinoma (NPC) who are sensitive to local treatment of metastases. Here, we aimed to establish a prognostic model for survival and individualize treatments for patients with metastatic NPC. Data were collated from 240 NPC patients diagnosed with metachronous metastasis between 2006 and 2020 who received palliative chemotherapy with or without local treatment. Multivariable Cox regression was implemented to construct a nomogram which had a concordance index of 0.764 when predicting 1-, 3-, and 5-year overall survival (OS). We then classified patients according to risk, creating low- and high-risk groups using the nomogram. Differences in OS between the two groups were significant (\(P<0.001\)). In the low-risk group, the OS for patients who received local treatment was longer than those without (\(P=0.009\)). This novel nomogram shows good performance in classifying patients according to risk and may also be a promising tool for determining who responds best to local treatment. Further validation using external center data is warranted.

Keywords: nasopharyngeal carcinoma, metastasis, prognostic model, treatment, overall survival

Introduction

Nasopharyngeal carcinoma (NPC) is one of the most common malignancies in head and neck cancers. In 2018 alone, there were approximately 129,000 recorded NPC cases with 73,000 NPC-related deaths worldwide\textsuperscript{[1]}. NPC generally responds to radiotherapy and chemotherapy, with radiotherapy being to frontline therapy for NPC. In recent years, the development of intensity-modulated radiotherapy (IMRT) has substantially improved the locoregional control rate for NPC patients. However, distant metastasis constitutes the primary cause of treatment failure\textsuperscript{[2]}. Indeed, even after definitive chemoradiotherapy, 15\%–30\% of non-metastatic NPC cases develop distal metastasis\textsuperscript{[3–5]}.
Conventionally, distant metastases are considered an incurable systemic element of disease progression which is generally treated using palliative approaches. The National Comprehensive Cancer Network (NCCN) guidelines recommend platinum-based palliative chemotherapy (PCT) for metastatic NPC. First-line chemotherapeutics studies have highlighted a median survival for metastatic NPC patients ranging from 12.1 to 22.1 months[6–9]. However, metastatic disease comprises a broad spectrum of characteristics and prognosis. Hellman and Weichselbaum proposed the concept of "oligometastases", whereby oligometastatic diseases spread to specific organs despite initially having a limited capacity to do so[9]. Therefore, localized treatments may be effective within the primary foci or metastatic lesions. In the past few years, local treatments for metastatic NPC have become the focus of interest for many researchers. For example, a randomized phase III study found that locoregional radiotherapy targeting primary tumors and metastatic lymph nodes following chemotherapy, significantly improves survival among chemo-sensitive patients with synchronous metastatic NPC[10]. Additionally, several retrospective studies have shown that local treatment of metastases can improve survival in patients with metastatic NPC[11–13]. Although, existing studies have not identified suitable candidates for local treatment in metastatic NPC.

Lacking an established standard for treating metastatic NPC may be due to the fact that there is no consensus around risk. Metastatic NPC patients are not an homogeneous group of people and there are within and between individual differences in terms of responses to treatment. This creates a whole host of unknown and there are, very few prospective studies which have assessed localized treatments of metastatic lesions. Therefore, we cannot confer survival benefits associated with each treatment modality for patients with metastatic NPC. It is reasonable to suggest that an individualized predictive model is needed to disentangle factors related to survival and it may then be possible to develop more individualized treatment strategies. Here, we developed a prognostic nomogram to identify NPC patients with metachronous metastasis, who would benefit most from local treatments.

Patients and methods

Patient population

Data from 347 NPC patients were collated and retrospectively reviewed. All patients had been diagnosed with metastatic NPC at the Affiliated Cancer Hospital of Nanjing Medical University (China) between January 2006 and December 2020. Patients were considered eligible according to the following criteria: (1) patients with histopathologically confirmed primary NPC; (2) those who had received locoregional radiotherapy with IMRT; and (3) those who had metachronous metastatic disease diagnosed more than 6 months after initial diagnosis[14–15].

Patients were excluded if they had: (1) synchronous metastatic disease; (2) or a Karnofsky Performance Score of <70 when diagnosed with distant metastasis; (3) other malignancies; (4) incomplete clinical or survival data; or (5) those who refused antitumor treatment(s). The 8th edition of the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) system was implemented to restage patients. The study was conducted in accordance with the Declaration of Helsinki. The study was approved by the Research Ethics Committee of Jiangsu Cancer Hospital (Approval No. 2021-020), and individual consent for this retrospective study was not deemed necessary.

Baseline data

During the initial treatment period, all patients received radical IMRT to the nasopharynx and neck using simultaneous integrated boost with 6 MV X-ray radiation in our center. Pretreatment assessments included physical examination, electrocardiogram, chest X-ray, as well as hematologic and biochemical profiling.

An abnormal elevation in Epstein-Barr virus (EBV) DNA was considered a factor signifying potential disease relapse. One hundred and eighteen patients underwent EBV DNA detection pretreatment. Pathological analysis of metastatic lesions was established as the gold standard for diagnosing metastases. When pathological findings were unavailable, diagnosis was based on a multimodality imaging system, which included contrast-enhanced computed tomography (CT) of the chest and abdomen, whole-body bone scans, and positron emission tomography (PET-CT).

The total of metastatic lesions was calculated according to image findings, of which 1–5 lesions were defined as oligometastic. More than five lesions was defined as polymetastatic. Locoregional recurrence was confirmed using fiberoptic endoscopy of the nasopharynx and magnetic resonance imaging (MRI) scans of the head and neck.

Treatment

All patients received PCT according to previous chemotherapy regimens and toxicity tolerance after
first distant failure. The median PCT cycles was four, ranging from 1 to 12. PCT regimens included platinum plus 5-fluorouracil, taxane plus platinum, taxane plus platinum with 5-fluorouracil, and gemcitabine plus platinum (GP).

After receiving chemotherapy, 146 patients received local treatment for metastatic lesions, while the remaining patients did not. One or more localized treatments were administered to these patients of whom 16 underwent surgery (1, 11, and 4 cases with liver, lung, and distant lymphatic metastasis, respectively). One hundred and thirty-one patients received radiotherapy for one or more metastatic lesions of whom five received radiofrequency ablation for liver metastases.

Among patients who received radiotherapy, 19 received stereotactic body radiosurgery (SBRT), including seven with liver metastases and 12 with lung metastases. Radiation doses ranged from 30 to 66 Gy (2–10 Gy/fraction), with a median biologically effective dose of 60 Gy (range: 35–100).

**Follow-up**

Follow-ups were arranged every three months for the first 2 years and then every 6 to 12 months thereafter, until death or the last follow-up date (June 30, 2021). During the follow-up period, nasopharyngoscopy, contrast-enhanced MRI of nasopharynx and neck, and contrast-enhanced CT of chest and abdomen were performed. PET-CT was considered if necessary. The disease-free interval (DFI) was calculated using the date of initial NPC diagnosis until the diagnosis of distant metastasis. OS was considered, the primary endpoint of this study and was calculated from the date of diagnosis of metastasis to the date of last follow-up or death.

**Statistical analysis**

SPSS version 22.0 (IBM, USA) was used to perform statistical analysis. All variables are categorical, and intergroup comparisons were performed using Pearson's chi-squared test or Fisher's test. Cox's proportional hazard model was implemented to investigate the independence of prognostic factors related to OS. Hazard ratios (HR) and corresponding 95% confidence intervals (CI) are reported as effect estimates. Variables that met the predetermined significance threshold (P<0.1) under univariable analysis were entered into multivariable analysis. Two-tailed P<0.05 were considered statistically significant.

R software (version 4.0.3) was used for model building. The prognostic nomogram was constructed using the "rms" package with independent prognostic factors.[16] The "nomogramFormula" package calculated scores for each variable as well as a total score for each patient.[17] The "nomogramEX" package was used to extract formulas from the nomogram.[18] The concordance index (C-index) and calibration curves were used to assess model performance. Kaplan-Meier curves were used to estimate the 1-, 3-, and 5-year OS rates and differences between groups of patients.

**Results**

**Clinical characteristics**

A total of 240 NPC patients with metachronous metastasis were considered eligible (Fig. 1). All patients had histologically confirmed non-keratinizing NPC at initial diagnosis. The median age was 49 years (range: 11–78), and 78.8% of this sample were male. 32.5% (n=78) of this sample developed distant metastasis within 12 months following the primary diagnosis (DFI≤12 months). The remaining patients developed distant metastasis after 12 months (DFI>12 months).

The incidence of lung, bone, liver, and distant nodal metastasis was 42.5%, 47.5%, 28.3%, and 28.3%, respectively. Oligometastatic disease was detected in 60.4% (n=145) patients (63 with single metastatic lesions and 82 with 2 to 5 lesions). 39.6% (n=95) patients had polymetastatic disease (>5 lesions). 13.8% (n=33) had simultaneous locoregional recurrence. One hundred and twenty (50%) patients received ≥4 cycles of PCT after the first distant failure, and the remainder received <4 cycles. Demographics and the clinical characteristics of patients with metastatic NPC have been summarized and are provided in Table 1.

The median follow-up duration was 23 months (ranging from 1 to 176 months). 169 patients died during this study period. The 1-, 3-, and 5-year OS rates were 76.1%, 39.8%, and 24.8%, respectively.

**Independent prognostic factors**

The results of univariable and multivariable regression analysis are provided in Table 2. Six variables were considered statistically significant intergroup differences, including sex, DFI, liver metastasis, number of metastatic lesions, locoregional recurrence, and number of PCT cycles. These variables were identified as independent prognostic factors for OS in metastatic NPC patients. Specifically, being female was associated with a better prog-
nosity (HR=1.690; 95% CI: 1.095–2.542; P=0.012).

Patients who developed distant metastasis within 12 months after the primary diagnosis (DFI≤12) generally had poorer prognosis (HR=0.650; 95% CI: 0.466–0.908; P=0.012). Concerning the site of metastasis, liver metastasis (HR=1.580; 95% CI: 1.113–2.243; P=0.011) was an adverse prognostic factor for survival. The number of metastatic lesions had a profound impact on clinical outcomes compared to those with single lesions. Patients with 2 to 5 or more than 5 lesions had a significantly poorer prognosis (HR=2.875; 95% CI: 1.749–4.725 and HR=7.955; 95% CI: 4.597–13.766; both P<0.001).

Concurrent locoregional recurrence with distant metastasis conferred an increased mortality risk (HR=2.079; 95% CI: 1.338–3.230; P=0.001). Additionally, patients who received ≥4 cycles of PCT experienced significantly improved OS than compared to those with <4 cycles (HR=0.403; 95% CI: 0.281–0.576; P<0.001).

Developing and assessing the nomogram

Based on the predictors derived through multivariable regression analysis, a prognostic nomogram was constructed to predict the 1-, 3-, and 5-year survival (Fig. 2). In order to use the nomogram, each variable subtype had to correspond with score on a specific point scale. The total score was then calculated using scores which corresponded to each variable, to estimate the 1-, 3-, and 5-year OS rates (Supplementary Table 1, available online). Nomogram formulas for generating OS probabilities were calculated, as follows:

\[
\text{OS rates} = \frac{1}{1 + e^{-\text{score}}}
\]

Nomogram formulas for generating OS probabilities were calculated, as follows:

\[
\text{Nomogram  formulas  for  generating  OS  probabilities}
\]

Supplementary Table 1

| Characteristics | Total patients (n=240) | LT+PCT (n=146) | PCT (n=94) | P-value |
|-----------------|------------------------|----------------|-----------|---------|
| Age (years)     |                        |                |           |         |
| <49             | 117 (48.8)             | 76 (52.1)      | 41 (43.6) | 0.202   |
| ≥49             | 123 (51.2)             | 70 (47.9)      | 53 (56.4) |         |
| Sex             |                        |                |           |         |
| Female          | 51 (21.2)              | 26 (17.8)      | 25 (26.6) | 0.104   |
| Male            | 189 (78.8)             | 120 (82.2)     | 69 (73.4) |         |
| BMI             |                        |                |           | 0.653   |
| <23             | 109 (45.4)             | 68 (46.6)      | 41 (43.6) |         |
| ≥23             | 131 (54.6)             | 78 (53.4)      | 53 (56.4) |         |
| KPS             |                        |                |           | 0.644   |
| ≤80             | 104 (43.3)             | 65 (44.5)      | 39 (41.5) |         |
| >80             | 136 (56.7)             | 81 (55.5)      | 55 (58.5) |         |
| T stagea       |                        |                |           | 0.126   |
| T1              | 27 (11.3)              | 11 (7.5)       | 16 (17.0) |         |
| T2              | 43 (17.9)              | 27 (18.5)      | 16 (17.0) |         |
| T3              | 75 (31.2)              | 50 (34.2)      | 25 (26.6) |         |
| T4              | 95 (39.6)              | 58 (39.8)      | 37 (39.4) |         |
| N stageb       |                        |                |           | 0.940   |
| N0              | 3 (1.2)                | 2 (1.4)        | 1 (1.1)   |         |
| N1              | 77 (31.2)              | 48 (32.9)      | 29 (30.9) |         |
| N2              | 109 (45.4)             | 64 (43.8)      | 45 (47.9) |         |
| N3              | 51 (21.3)              | 32 (21.9)      | 19 (20.1) |         |
| DFI (months)    |                        |                |           | 0.682   |
| <12             | 78 (32.5)              | 46 (31.5)      | 32 (34.0) |         |
| ≥12             | 162 (67.5)             | 100 (68.5)     | 62 (66.0) |         |
| Lung metastasis |                        |                |           | <0.001  |
| No              | 138 (57.5)             | 98 (67.1)      | 40 (42.6) |         |
| Yes             | 102 (42.5)             | 48 (32.9)      | 54 (57.4) |         |
| Bone metastasis |                        |                |           | <0.001  |
| No              | 126 (52.5)             | 61 (41.8)      | 65 (69.1) |         |
| Yes             | 114 (47.5)             | 85 (58.2)      | 29 (30.9) |         |
| Liver metastasis|                        |                |           | 0.001   |
| No              | 172 (71.7)             | 116 (79.5)     | 56 (59.6) |         |
| Yes             | 68 (28.3)              | 30 (20.5)      | 38 (40.4) |         |
| Distant nodal metastasis |            |                |           | <0.001  |
| No              | 165 (68.8)             | 115 (78.8)     | 50 (53.2) |         |
| Yes             | 75 (31.2)              | 31 (21.2)      | 44 (46.8) |         |
| No. of metastatic lesions |          |                |           | <0.001  |
| 1               | 63 (26.2)              | 50 (34.3)      | 13 (13.8) |         |
| 2–5             | 82 (34.2)              | 50 (34.2)      | 32 (34.0) |         |
| >5              | 95 (39.6)              | 46 (31.5)      | 49 (52.2) |         |
| Pretreatment EBV DNA |                |                |           | 0.148   |
| Undetectable    | 49 (20.4)              | 35 (24.0)      | 14 (14.9) |         |
| Detectable      | 69 (28.8)              | 37 (25.3)      | 32 (34.0) |         |
| Not available   | 122 (50.8)             | 74 (50.7)      | 48 (51.1) |         |
| Locoregional recurrence |       |                |           | 0.051   |
| No              | 207 (86.2)             | 131 (89.7)     | 76 (80.9) |         |
| Yes             | 33 (13.8)              | 15 (10.3)      | 18 (19.1) |         |
| No. of PCT cycles |                  |                |           | 0.002   |
| ≤4              | 120 (50.0)             | 85 (58.2)      | 35 (37.2) |         |
| >4              | 120 (50.0)             | 61 (41.8)      | 59 (62.8) |         |

*Age at diagnosis of distant metastasis. According to the 8th UICC/AJCC staging system. LT: local treatment of metastases; PCT: palliative chemotherapy; BMI: body mass index; KPS: Karnofsky performance score; DFI: disease-free interval; EBV: Epstein-Barr virus; No.: number.
| Variables                        | Univariable | Multivariable |
|---------------------------------|-------------|---------------|
|                                 | HR (95% CI) | P-value       | HR (95% CI) | P-value |
| Age (years)                     |             |               |
| <49                             | Reference   |               |
| ≥49                             | 1.137 (0.839–1.542) | 0.407       |
| Sex                             |             |               |
| Female                          | Reference   |               |
| Male                            | 1.484 (1.009–2.182) | 0.045       |
|                                |             |               |
| BMI                             |             |               |
| <23                             | Reference   |               |
| ≥23                             | 0.991 (0.732–1.342) | 0.952       |
| KPS                             |             |               |
| ≤80                             | Reference   |               |
| >80                             | 0.918 (0.677–1.244) | 0.580       |
| T stage                         |             |               |
| T1                              | Reference   |               |
| T2                              | 1.057 (0.602–1.857) | 0.847       |
| T3                              | 0.847 (0.507–1.415) | 0.526       |
| T4                              | 0.722 (0.436–1.196) | 0.206       |
| N stage                         |             |               |
| N0                              | Reference   |               |
| N1                              | 3.265 (0.451–23.624) | 0.241       |
| N2                              | 3.572 (0.496–25.717) | 0.206       |
| N3                              | 4.840 (0.663–35.327) | 0.120       |
| DFI (months)                    |             |               |
| <12                             | Reference   |               |
| >12                             | 0.604 (0.442–0.825) | 0.001       |
| Lung metastasis                 |             |               |
| No                              | Reference   |               |
| Yes                             | 0.754 (0.554–1.025) | 0.072       |
| Bone metastasis                 |             |               |
| No                              | Reference   |               |
| Yes                             | 1.397 (1.033–1.890) | 0.030       |
| Liver metastasis                |             |               |
| No                              | Reference   |               |
| Yes                             | 1.737 (1.261–2.393) | 0.001       |
| Distant nodal metastasis        |             |               |
| No                              | Reference   |               |
| Yes                             | 1.659 (1.210–2.276) | 0.002       |
| No. of metastatic lesions       |             |               |
| 1                               | Reference   |               |
| 2–5                             | 1.746 (1.115–2.736) | 0.015       |
| >5                              | 4.713 (3.052–7.279) | <0.001      |
| Locoregional recurrence         |             |               |
| No                              | Reference   |               |
| Yes                             | 1.473 (0.974–2.229) | 0.067       |
| No. of PCT cycles               |             |               |
| <4                              | Reference   |               |
| ≥4                              | 0.630 (0.465–0.853) | 0.003       |

*Age at diagnosis of distant metastasis. †According to the 8th UICC/AJCC staging system. BMI: body mass index; KPS: Karnofsky performance score; DFI: disease-free interval; No.: number; PCT: palliative chemotherapy; HR: hazard ratio; CI: confidence interval.
The C-index of the nomogram was 0.764 (95% CI: 0.649–0.806), which suggests good accuracy for predicting survival. Calibration curves obtained using the bootstrap method showed good fitness between predicted and observed survival (Fig. 3).

**Risk stratification**

We used the median total score from the prognostic nomogram to stratify the cohort into the low- (risk score 0–122) and high-risk (risk score 123–260) groups (Table 3). Baseline characteristics of low- and high-risk patients have been provided in the Supplementary Tables 2 and 3 (available online), respectively. The 1-, 3-, and 5-year OS rates of patients in each group are also summarized in Supplementary Table 4 (available online).

Kaplan-Meier curves for OS highlighted significant intergroup differences (P<0.001; Fig. 4), which also suggests this model is effective at stratifying metastatic NPC patients. With an estimated median OS of 45.0 months, the 1-, 3-, and 5-year OS rates of patients in the low-risk group were 93.6%, 60.0%, and 41.1% respectively, which were all significantly higher than those in the high-risk group.

**Fig. 2** Prognostic nomogram for predicting the 1-, 3-, and 5-year overall survival in patients with metastatic nasopharyngeal carcinoma. The nomogram was generated from the independent prognostic factors including sex, DFI, liver metastasis, No. of metastatic lesions, locoregional recurrence, and No. of PCT cycles. To use the nomogram, calculate the total points from each variable points, then draw a straight line down to predict the overall survival at 1-, 3-, and 5-years. DFI: disease-free interval; No.: number; PCT: palliative chemotherapy.

**Fig. 3** Calibration curves of the nomogram for predicting the 1-, 3-, and 5-year overall survival. The x-axis represents the nomogram predicted probability of OS; and the y-axis represents the actual value. OS: overall survival.
Table 3  Characteristics of low- and high-risk groups defined by the prognostic nomogram n (\%)

| Variable                          | Low-risk (n=116) | High-risk (n=124) | P-value |
|-----------------------------------|-----------------|------------------|---------|
| Age (years)\(^a\)                 |                 |                  | 0.240   |
| <49                               | 52 (44.8)       | 65 (52.4)        |         |
| ≥49                               | 64 (55.2)       | 59 (47.6)        |         |
| Sex                               |                 |                  | 0.020   |
| Female                            | 32 (27.6)       | 19 (15.3)        |         |
| Male                              | 84 (72.4)       | 105 (84.7)       |         |
| BMI                               |                 |                  | 0.390   |
| <23                               | 56 (48.3)       | 53 (42.7)        |         |
| ≥23                               | 60 (51.7)       | 71 (57.3)        |         |
| KPS                               |                 |                  | 0.330   |
| ≤80                               | 54 (46.6)       | 50 (40.3)        |         |
| >80                               | 62 (53.4)       | 74 (59.7)        |         |
| T stage\(^a\)                     |                 |                  | 0.852   |
| T1                                | 11 (9.5)        | 16 (1.9)         |         |
| T2                                | 21 (18.1)       | 22 (17.7)        |         |
| T3                                | 38 (32.8)       | 37 (29.8)        |         |
| T4                                | 46 (39.6)       | 49 (39.6)        |         |
| N stage\(^a\)                     |                 |                  | 0.530   |
| N0                                | 2 (1.7)         | 1 (0.8)          |         |
| N1                                | 41 (35.3)       | 36 (29.0)        |         |
| N2                                | 52 (44.8)       | 57 (46.0)        |         |
| N3                                | 21 (18.2)       | 30 (24.2)        |         |
| DFI (months)                      |                 |                  | 0.034   |
| ≤12                               | 30 (25.9)       | 48 (38.7)        |         |
| >12                               | 86 (74.1)       | 76 (61.3)        |         |
| Lung metastasis                   |                 |                  | 0.219   |
| No                                | 62 (53.4)       | 76 (61.3)        |         |
| Yes                               | 54 (46.6)       | 48 (38.7)        |         |
| Bone metastasis                   |                 |                  | 0.009   |
| No                                | 71 (61.2)       | 55 (44.4)        |         |
| Yes                               | 45 (38.8)       | 69 (55.6)        |         |
| Liver metastasis                  |                 |                  | 0.005   |
| No                                | 93 (80.2)       | 79 (63.7)        |         |
| Yes                               | 23 (19.8)       | 45 (36.3)        |         |
| Distant nodal metastasis          |                 |                  | <0.001  |
| No                                | 96 (82.8)       | 69 (55.6)        |         |
| Yes                               | 20 (17.2)       | 55 (44.4)        |         |
| No. of metastatic lesions         |                 |                  | <0.001  |
| 1                                 | 60 (51.7)       | 3 (2.4)          |         |
| 2–5                               | 55 (45.7)       | 29 (23.4)        |         |
| >5                                | 3 (2.6)         | 92 (74.2)        |         |
| Locoregional recurrence            |                 |                  | 0.138   |
| No                                | 104 (89.7)      | 103 (83.1)       |         |
| Yes                               | 12 (10.3)       | 21 (16.9)        |         |
| No. of PCT cycles                 |                 |                  | <0.001  |
| <4                                | 44 (37.9)       | 76 (61.3)        |         |
| ≥4                                | 72 (62.1)       | 48 (38.7)        |         |

\(^a\)Age at diagnosis of distant metastases. \(^a\)According to the 8th UICC/AJCC staging system. BMI: body mass index; KPS: Karnofsky performance score; DFI: disease-free interval; No.: number; PCT: palliative chemotherapy; LT: local treatment of metastases.

Fig. 4  Kaplan-Meier survival curves of patients with metastatic nasopharyngeal carcinoma in different risk groups. Patients were classified into low- and high-risk groups according to the risk score derived from the nomogram, and the intergroup difference in overall survival was statistically significant.

Local treatment in different risk groups

To select patients who might benefit from local treatment of metastases, we further compared OS for patients with or without local treatment and within each risk group. For low-risk patients who received PCT plus local treatment or PCT alone, the 1-, 3-, and 5-year OS rates were 94.9%, 67.3%, 57.0%, and 91.9%, 53.1%, 21.7%, respectively (P=0.009, Fig. 5A). In the high-risk group, the 1-, 3-, and 5-year OS rates of patients with or without local treatment were 56.2%, 18.9%, 7.2%, and 63.2%, 18.8%, 5.6%, respectively (P=0.927, Fig. 5B).

According to multivariable analysis (Table 4), patients in the low-risk group, who received PCT plus local treatment, had a significantly better prognosis than those who received PCT alone (HR=0.570; 95% CI: 0.343–0.947; P=0.030). However, there was no significant intergroup difference in terms of survival between the two treatment groups in the high-risk group (HR=0.994; 95% CI: 0.678–1.458; P=0.975).

Discussion

Significant progress has been made in localized
controls for NPC due to the development of IMRT and imaging systems which are now more precise at defining tumors and identifying organs at risk. However, distant metastases are still a challenge for patients with NPC, and there is no consensus regarding treatment strategies. According to the GEM20110714 study\(^\text{[7]}\), the preferred first-line regimen of GP in metastatic NPC resulted in a median OS of 22.1 months and 1-, 3-, and 5-year OS rates of 79.9%, 31.8%, and 19.2%, respectively. However, prognosis for metastatic NPC patients has significant heterogeneity in the real world due to the broad spectrum of metastatic diseases and the use of various treatments. In this study, we established an easy-to-use nomogram for predicting OS for patients with metastatic NPC. This novel model appears to perform well at identifying candidates who would benefit from local treatments.

According to the NCCN guidelines, systemic chemotherapy remains the cornerstone of the therapeutic management of metastatic NPC patients. Consistent with previous reports\(^\text{[19–20]}\), this study showed that patients who received more than 4 cycles of PCT had a significantly longer overall survival compared to those administered with fewer than four cycles. However, adequate chemotherapy does not mean that the course of chemotherapy should be extended indefinitely. Numerous reports have proposed that appropriate local treatment could improve the local control of metastatic lesions and confers survival benefits on some patients. For example, Huang et al\(^\text{[11]}\) reported that NPC patients with limited liver metastases treated by a partial hepatectomy achieved a median OS of 45.2 months, which was obviously elevated compared to 14.1 months in the control group. Likewise in patients with lung-only metastases from NPC, pulmonary metastasectomy provided reliable local control and survival benefits with significantly higher 5-year survival rates than in the nonsurgically treated group (75.5% vs. 47.8%, \(P=0.005\))\(^\text{[21]}\). A retrospective study also revealed that chemoradiotherapy conferred a better prognosis than chemotherapy alone in NPC patients with bone metastases\(^\text{[22–23]}\).

In clinical practice, however, not all metastatic lesions of NPC will respond to local treatments. Based on the nomogram we established in this study, patients with metastatic NPC were stratified into low- and high-risk groups. We found that the survival benefit associated with local treatment which was solely observed in those considered at low-risk. There was no additional survival benefit in high-risk patients

### Table 4 Multivariable analysis of overall survival for low- and high-risk groups

| Variable                  | Low-risk          |         | High-risk         |         |
|---------------------------|-------------------|---------|-------------------|---------|
|                           | HR (95% CI)       | \(P\)-value | HR (95% CI)       | \(P\)-value |
| Treatment (LT+PCT vs. PCT) | 0.570 (0.343–0.947) | 0.030     | 0.994 (0.678–1.458) | 0.975       |
| Risk score                | 1.018 (1.007–1.028) | 0.001     | 1.022 (1.014–1.029) | <0.001     |

LT: local treatment of metastases; PCT: palliative chemotherapy; HR: hazard ratio; CI: confidence interval.
receiving local treatment compared with PCT alone. This may explain why local treatment did not
demonstrate a statistically significant difference in OS
across the entire cohort and further demonstrates the
validity of our model. Therefore, clinicians can use
our model to determine who responds best to local
treatment and make individualized treatment
recommendations. Our study fills the gap where
previous studies failed to identify who would benefit
from local treatment of metastases. Increasingly,
evidence suggests that applying, potentially curative
metastasis-directed radiotherapy for oligometastatic
disease in various solid tumors, significantly improves
survival and was associated with low treatment-related
toxicity[24–27]. Due to the advancement of
radiotherapeutic technologies, such as SBRT, ablative
radiotherapy doses can be safely delivered to sites of
metastasis. Regrettably, only 19 patients in our study
underwent SBRT for metastatic lesions, and the
sample size was too small for further analysis.

The definition of oligometastatic NPC has been
widely discussed, and the generally accepted
definition notes the presence of up to five metastatic
lesions on imaging. In the present study, multivariable
Cox regression indicated that the number of metastatic
lesions was the most decisive prognostic parameter.
Consistent with results reported in previous
studies[20, 28–29], the prognosis of patients with
oligometastatic disease (1-5 lesions) is significantly
better than that for those with polymetastatic disease
(>5 lesions). The presence of a single lesion predicted
superior survival outcomes than that of multiple
metastatic lesions, possibly because a single lesion is
more amenable to radical local treatment in the clinic.
It is worth noting that we only included patients with
metachronous metastatic disease or what is commonly
referred to as post-treatment metastasis. Unlike those
with synchronous metastatic NPC, patients with
metachronous metastasis have already received
aggressive radiotherapy to the primary foci. In the
present study, concurrent locoregional recurrence was
identified as a poor prognostic factor for metastatic
NPC. Locoregional recurrent NPC after initial
radiotherapy is likely to be radioresistant. Besides, an
uncontrolled primary tumor may promote distant
metastasis. It is currently unclear whether a
locoregionally controlled primary tumor should
become a precondition for diagnosing the
oligometastatic disease, but it should be considered a
crucial prognostic parameter for metastatic NPC.

Generally, patients with oligometastatic disease
tend to have a low tumor burden and are more likely
to receive aggressive metastasis-directed therapy, such
as surgery or high-dose irradiation. In contrast,
patients with polymetastatic disease are generally
considered to have no curative potential and receive
palliative systemic therapy. Nonetheless, in our study,
not all cases with oligometastases were included in the
low-risk group, and a proportion of patients with
polymetastatic disease achieved better survival
following comprehensive treatment. Metastatic status
changes throughout the disease dynamically, and
patients with polymetastatic disease may achieve
oligometastatic status during successful systemic
therapy[14–15]. Moreover, oligometastatic disease is
diagnosed solely based on imaging because no
biomarker is currently available for identifying
patients with oligometastatic disease, in the clinic.
However, imaging modalities fail to detect occult
metastasis early, and biomarkers to assess tumor
burden dynamics for surveillance during and after
treatment are needed.

There are several limitations of this study that need
to be noted. First, the retrospective study might result
in a potential selection bias. Second, as the limitation
of sample size and center number, we failed to
conduct external validation. Third, only 118 patients
in this study cohort underwent pretreatment plasma
EBV DNA detection. Thus, it was hard to estimate the
potential prognostic value of EBV DNA. Finally,
innovations in chemotherapeutic regimens and
advances in radiotherapeutic technology have
ininitely changed treatment protocols, although the
general treatment principles have remained unchanged.

In conclusion, we established an easy-to-use
nomogram which demonstrated good performance in
predicting survival and provided individualized
stratification for patients with metastatic NPC. Using
the prognostic model, patients who are sensitive to
local treatment can be identified. In the future,
multicenter external validation and prospective studies
are needed to generalize the use of our model.

Acknowledgments

This work was supported by the National Natural
Science Foundation of China (Grant No. 81872192)
and China International Medical Foundation (Grant
No. Z-2014-06-19392).

References

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer
statistics 2018: GLOBOCAN estimates of incidence and
mortality worldwide for 36 cancers in 185 countries[J]. CA
Cancer J Clin, 2018, 68(6): 394–424.
[2] Mao Y, Tang L, Chen L, et al. Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy[J]. Chin J Cancer, 2016, 35(1): 103.

[3] Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience[J]. Int J Radiat Oncol Biol Phys, 2002, 53(1): 12–22.

[4] Lai S, Li W, Chen L, et al. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?[J]. Int J Radiat Oncol Biol Phys, 2011, 80(3): 661–668.

[5] Wu L, Liu Y, Jiang N, et al. Ten-year survival outcomes for patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: an analysis of 614 patients from a single center[J]. Oral Oncol, 2017, 69: 26–32.

[6] Yeo W, Leung TWT, Leung SF, et al. Phase II study of the combination of carboplatin and 5-fluorouracil in metastatic nasopharyngeal carcinoma[J]. Cancer Chemother Pharmacol, 1996, 38(5): 466–470.

[7] Hong S, Zhang Y, Yu G, et al. Gemcitabine plus cisplatin versus fluouracil plus cisplatin as first-line therapy for recurrent or metastatic nasopharyngeal carcinoma: final overall survival analysis of GEM20110714 phase III study[J]. J Clin Oncol, 2021, 39(29): 3273–3282.

[8] Au E, Ang PT. A phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma[J]. Ann Oncol, 1994, 5(1): 87–89.

[9] Weichselbaum R, Hellman S. Oligometastases revisited[J]. Nat Rev Clin Oncol, 2011, 8(6): 378–382.

[10] You R, Liu Y, Huang P, et al. Efficacy and safety of locoregional radiotherapy with chemotherapy vs chemotherapy alone in de novo metastatic nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial[J]. JAMA Oncol, 2020, 6(9): 1345–1352.

[11] Huang J, Li Q, Zheng Y, et al. Partial hepatectomy for liver metastases from nasopharyngeal carcinoma: a comparative study and review of the literature[J]. BMC Cancer, 2014, 14: 818.

[12] Jin Y, Cai Y, Cao Y, et al. Radiofrequency ablation combined with systemic chemotherapy in nasopharyngeal carcinoma liver metastases improves response to treatment and survival outcomes[J]. J Surg Oncol, 2012, 106(3): 322–326.

[13] Ma J, Wen Z, Lin P, et al. The results and prognosis of different treatment modalities for solitary metastatic lung tumor from nasopharyngeal carcinoma: a retrospective study of 105 cases[J]. Chin J Cancer, 2010, 29(9): 787–795.

[14] Lievens Y, Guckenberger M, Gomez D, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document[J]. Radiother Oncol, 2020, 148: 157–166.

[15] Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation[J]. Lancet Oncol, 2020, 21(1): E18–E28.

[16] Harrell FE Jr. Rms: Regression Modeling Strategies[EB/OL]. [2021-03-18]. https://github.com/harrelfe/rms.

[17] Zhang J, Jin Z. nomogramFormula[EB/OL]. [2019-08-17]. https://github.com/yikeshu661/nomogramFormula.

[18] Du Z, Hao Y. nomogramEx: Extract Equations from a Nomogram[EB/OL]. [2017-08-29]. https://cran.r-project.org/web/packages/nomogramEx/index.html.

[19] Zheng W, Zong J, Huang C, et al. Multimodality treatment may improve the survival rate of patients with metastatic nasopharyngeal carcinoma with good performance status[J]. PLoS One, 2016, 11(1): e0146771.

[20] Tian Y, Zou W, Xiao W, et al. Oligometastases in AJCC stage IVc nasopharyngeal carcinoma: a subset with better overall survival[J]. Head Neck, 2016, 38(8): 1152–1157.

[21] Zhao Z, Liu D, Wang Y, et al. Pulmonary metastasectomy in patients with lung metastases from nasopharyngeal carcinoma[J]. Ann Surg Oncol, 2021, 28(8): 4542–4550.

[22] Shen L, Dong J, Li S, et al. MI stage subdivision and treatment outcome of patients with bone-only metastasis of nasopharyngeal carcinoma[J]. Oncologist, 2015, 20(3): 291–298.

[23] Cao X, Han Y, He L, et al. Risk subset of the survival for nasopharyngeal carcinoma patients with bone metastases: who will benefit from combined treatment?[J]. Oral Oncol, 2011, 47(8): 747–752.

[24] Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial[J]. Lancet, 2019, 393(10185): 2051–2058.

[25] Gomez DR, Tang C, Zhang J, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study[J]. J Clin Oncol, 2019, 37(18): 1558–1565.

[26] Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial[J]. JAMA Oncol, 2018, 4(1): e173501.

[27] Ruers T, van Coevorden F, Punt CJA, et al. Local treatment of unrespectable colorectal liver metastases: results of a randomized phase II trial[J]. J Natl Cancer Inst, 2017, 109(9): djx015.

[28] Li W, Lv S, Liu G, et al. Development of a prognostic model to identify the suitable definitive radiation therapy candidates in de novo metastatic nasopharyngeal carcinoma: a real-world study[J]. Int J Radiat Oncol Biol Phys, 2021, 109(1): 120–130.

[29] Chee J, Liu X, Eu D, et al. Defining a cohort of oligometastatic nasopharyngeal carcinoma patients with improved clinical outcomes[J]. Head Neck, 2020, 42(5): 945–954.